Last 44 quarters of trend data · Healthcare · Biotechnology
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 | Q1 '21 | Q4 '20 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -8.28 | — | — | — | — | — | — | — | — | — | — | 10.58 | — | 0.93 | — | — | — | — | 2.80 | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | 1102.50 | — | — | — | — | — | 45.11 | 21.45 | 1.02 | 2.31 | 5.00 | 1.23 | 1.33 | 0.34 | 1.36 | 1.99 | 2.83 | 3.92 | 0.91 | 12.97 | 5.92 |
| — | — | — | — | — | — | +801.9% | +1643.3% | -23.2% | +575.8% | +268.1% | -38.3% | -53.0% | -91.3% | +49.0% | -84.6% | -52.1% | -69.2% | -91.8% | +39.8% | -66.4% | |
| P/B Ratio | 8.61 | 3.52 | 1.51 | 2.16 | 1.60 | 0.61 | 0.42 | — | — | 10.58 | 6.61 | 4.79 | — | 6.14 | — | 11.44 | 3.80 | — | 7.59 | 66.05 | 8.24 |
| — | +480.6% | +263.1% | — | — | -94.3% | -93.7% | — | — | +72.4% | — | -58.2% | — | — | — | -82.7% | -53.9% | — | +107.6% | +3681.3% | +144.0% | |
| P/FCF | — | — | — | — | — | — | — | — | — | — | 9.38 | — | — | 0.50 | — | — | — | — | 8.75 | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — | 7.25 | — | 0.07 | — | — | — | — | 1.74 | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — | 7.33 | — | 0.07 | — | — | — | — | 1.78 | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 | Q1 '21 | Q4 '20 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 100.0% | — | — | — | — | — | 100.0% | -508.3% | 93.5% | -12.7% | 100.0% | 100.0% | 100.0% | 100.0% | -145.4% | 100.0% | -163.2% | 100.0% | 100.0% | 100.0% | 100.0% |
| — | — | — | — | — | — | 0.0% | -608.3% | -6.5% | -112.7% | +168.8% | 0.0% | +161.3% | 0.0% | -245.4% | 0.0% | -263.2% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Operating Margin | -13811.9% | — | — | — | — | — | -31782.8% | -877.9% | -34.5% | -48.5% | -132.6% | 10.7% | -129.8% | 36.6% | -211.0% | -256.9% | -232.1% | -254.9% | 32.8% | -756.7% | -577.8% |
| — | — | — | — | — | — | -23873.7% | -8341.4% | +73.4% | -232.4% | +37.2% | +104.1% | +44.1% | +114.4% | -743.5% | +66.1% | +59.8% | +64.9% | +106.1% | -31.5% | +25.5% | |
| Net Margin | -13319.8% | — | — | — | — | — | -30201.7% | -1061.3% | -31.9% | -98.8% | -267.7% | 11.5% | -130.9% | 36.8% | -211.1% | -257.2% | -232.6% | -255.6% | 32.6% | -759.6% | -580.2% |
| — | — | — | — | — | — | -11183.5% | -9295.5% | +75.6% | -368.8% | -26.8% | +104.5% | +43.7% | +114.4% | -747.5% | +66.1% | +59.9% | +65.0% | +106.0% | -32.2% | +24.9% |
| Metric | TTM | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 | Q1 '21 | Q4 '20 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -219.0% | -18.0% | -8.0% | -15.4% | -37.5% | -13.0% | -161.2% | — | — | -77.7% | -64.5% | 48.6% | — | 2708.5% | — | -137.8% | -164.6% | -247.2% | 121.2% | -290.2% | -107.5% |
| — | -39.0% | +95.0% | — | — | +83.3% | -150.0% | — | — | -102.9% | — | +135.3% | — | +1195.7% | — | +52.5% | -53.2% | -397.0% | +414.7% | -814.0% | -232.5% | |
| ROA | -120.5% | -15.8% | -7.1% | -11.6% | -27.7% | -9.5% | -80.7% | -17.2% | -8.6% | -13.9% | -18.2% | 4.7% | -23.4% | 28.2% | -27.7% | -28.0% | -26.6% | -31.5% | 18.2% | -31.9% | -34.9% |
| — | -66.0% | +91.2% | +33.0% | -222.6% | +31.3% | -343.4% | -469.8% | +63.2% | -149.2% | +34.2% | +116.7% | +11.9% | +189.5% | -252.4% | +12.3% | +23.8% | -22.3% | +178.1% | -68.0% | -87.3% | |
| ROIC | — | -107.5% | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 | Q1 '21 | Q4 '20 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.02 | 0.00 | 0.00 | 0.02 | 0.02 | 0.03 | 0.03 | — | — | 0.54 | 0.29 | 0.04 | — | 0.18 | — | 0.74 | 0.23 | — | 0.34 | 3.51 | 0.74 |
| — | -86.2% | -85.8% | — | — | -93.7% | -88.9% | — | — | +203.2% | — | -95.0% | — | — | — | -78.8% | -68.4% | — | +30.8% | +1534.1% | +139.8% | |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — | 0.36 | — | 0.11 | — | — | — | — | 0.48 | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 4.25 | 4.62 | 16.45 | 3.87 | 4.25 | 3.54 | 4.25 | 0.72 | 0.90 | 1.62 | 1.98 | 2.23 | 1.09 | 1.93 | 1.16 | 1.62 | 2.11 | 1.41 | 1.80 | 1.28 | 1.48 |
| — | +30.7% | +286.9% | +440.5% | +371.1% | +118.3% | +114.7% | -67.9% | -17.1% | -16.2% | +70.5% | +37.6% | -48.3% | +37.0% | -35.5% | +26.2% | +42.1% | -20.6% | -18.8% | -52.8% | -32.0% | |
| Quick Ratio | 4.25 | 4.62 | 16.45 | 3.87 | 4.25 | 3.54 | 4.25 | 0.60 | 0.81 | 1.55 | 1.92 | 2.23 | 1.09 | 1.93 | 1.16 | 1.62 | 2.11 | 1.41 | 1.80 | 1.28 | 1.48 |
| — | +30.7% | +286.9% | +539.8% | +423.6% | +128.0% | +121.6% | -72.9% | -25.4% | -19.8% | +65.1% | +37.6% | -48.3% | +37.0% | -35.5% | +26.2% | +42.1% | -20.6% | -18.8% | -52.8% | -32.0% | |
| Interest Coverage | — | — | — | — | — | — | — | — | — | — | — | — | — | — | -2185.50 | -913.05 | -508.18 | -383.74 | 173.76 | -260.31 | -250.56 |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 44 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying CDTX stock.
Cidara Therapeutics, Inc.'s current P/E is -8.3x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Cidara Therapeutics, Inc.'s current operating margin is -13811.9%. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Cidara Therapeutics, Inc.'s business trajectory between earnings reports.